Study Compares Rivaroxaban, Warfarin With Apixaban for Cirrhosis, A-Fib

Follow Drugslib on

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

MONDAY, July 8, 2024 -- For patients with cirrhosis and nonvalvular atrial fibrillation (AF), initiators of rivaroxaban or warfarin versus apixaban have significantly higher rates of major hemorrhage, according to a study published online July 9 in the Annals of Internal Medicine.

Tracey G. Simon, M.D., M.P.H., from Brigham and Women's Hospital in Boston, and colleagues compared the effectiveness and safety of apixaban versus rivaroxaban and versus warfarin in a population-based propensity score-matched cohort study involving patients with cirrhosis and AF.

The researchers found that compared with apixaban initiators, rivaroxaban initiators had significantly higher rates of major hemorrhagic events (rate difference, 33.1 per 1,000 person-years; hazard ratio, 1.47); no significant differences were seen in the rates of ischemic events or death. Across subgroup and sensitivity analyses, the rates of major hemorrhage were consistently higher. Compared with apixaban initiators, warfarin initiators also had significantly higher rates of major hemorrhage (rate difference, 26.1 per 1,000 person-years; hazard ratio, 1.38), especially hemorrhagic stroke (rate difference, 9.7 per 1,000 person years; hazard ratio, 2.85).

"These findings suggest apixaban may offer safety benefits over both rivaroxaban and warfarin in patients with cirrhosis and AF engaged in routine clinical care," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-07-09 07:15

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords